Forgot Password?
Return to Course Listing

CME: Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

Activity Description / Statement of Need:

In this online CME self-learning program:

 

Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners.  The 2016 American Society of Hematology Annual Meeting & Exposition (ASH 2016) is no exception.  Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting. 

 

Acute Lymphoblastic Leukemia:

 

Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.These symptoms include: fatigue, malaise, or palpitations associated with anemia; fever with or without infection due to leukopenia or leukocytosis; and petechiae, and bleeding or bruising of the oral mucosa, skin, or gastrointestinal tract due to thrombocytopenia.  Although the precise etiology of ALL remains unknown, some cases have been associated with: exposure to ionizing, toxic chemicals, herbicides; genetic conditions such as Down’s syndrome, Fanconi syndrome, neurofibromatosis; viruses like human T-lymphotropic viruses 1 and 2 and Epstein-Barr virus.  After clinical suspicion is aroused, diagnostics include: a complete blood count, bone marrow biopsy, and flow cytometry.

 

 

Agenda:

 

Faculty member introduction, disclosures

Major findings from ASH 2016, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice

Application: patient cases

Summary, conclusion, and best practice recap

Target Audience:

Hematologist-oncologists, medical oncologists, oncology nurse practitioners, physician assistants who specialize in oncology, and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with ALL.


This program is supported by educational grants from Baxalta.


Release Date: January 19, 2017 -- Expiration Date: January 19, 2019

Faculty: Ibrahim Aldoss, MD

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASH 2016 relating to ALL and apply them to patient cases, where relevant, in the areas of genomics.
  • Summarize the most impactful findings presented at ASH 2016 relating to ALL and apply them to patient cases, where relevant, in the area of chemotherapy, including novel combinations.
  • Summarize the most impactful findings presented at ASH 2016 relating to ALL and apply them to patient cases, where relevant, in the areas of immunotherapy.
  • Summarize the most impactful findings presented at ASH 2016 relating to ALL and apply them to patient cases, where relevant, in the areas of hematopoietic cell transplantation.
  • Summarize the most impactful findings presented at ASH 2016 relating to ALL and apply them to patient cases, where relevant, in the areas of supportive care.

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure:  Ibrahm  Aldoss, MD has received financial compensation from participation at advisory boards and/or research grants from Helocyte.

 

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.

 

Commercial Support Disclosure: This program is supported by educational grants from Baxalta.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices

Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options